<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663725</url>
  </required_header>
  <id_info>
    <org_study_id>StrateGlio-1802</org_study_id>
    <secondary_id>2018-000410-38</secondary_id>
    <nct_id>NCT03663725</nct_id>
  </id_info>
  <brief_title>Treatment Intensification With Temozolomide in Adults With a Glioblastoma</brief_title>
  <acronym>StrateGlio</acronym>
  <official_title>Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association de Neuro-Oncologues d'Expression Francaise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to conflicting data on the optimal moment to start TMZ chemotherapy and the impact of&#xD;
      prolongation of the adjuvant phase with TMZ, the ANOCEF (Association des Neuro-Oncologues&#xD;
      d'Expression Francophone) group proposes this randomized trial comparing an intensified arm&#xD;
      (early TMZ and extended adjuvant TMZ until toxicity, progression or patient refusal) versus&#xD;
      the classical EORTC regimen as control (RT and concomitant TMZ started 4-6 weeks after&#xD;
      surgery followed by a number of adjuvant TMZ cycles strictly limited to 6) for primary GBM&#xD;
      adult patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 18 months after recruitment of the last patient</time_frame>
    <description>time interval from randomization to death whatever the cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>up to 18 months after recruitment of the last patient</time_frame>
    <description>from randomization until disease progression - reported and graded using the NCI-CTCAE v5.0 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 18 months after recruitment of the last patient</time_frame>
    <description>time interval from randomization to the first occurrence of progression according to RANO criteria as assessed by the treating physician, or death whatever the cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">535</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Intensified protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early Temozolomide (TMZ) Concomitant TMZ Adjuvant TMZ Prolonged TMZ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stupp protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concomitant Temozolomide (TMZ) Adjuvant TMZ</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensified protocol</intervention_name>
    <description>Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)</description>
    <arm_group_label>Intensified protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stupp protocol</intervention_name>
    <description>RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ</description>
    <arm_group_label>Stupp protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥18 years old&#xD;
&#xD;
          -  Histological diagnosis of de novo GBM (extemporaneous diagnosis or standard&#xD;
             pathological examination). In case of extemporaneous diagnosis, the patient can be&#xD;
             included. If the diagnosis is not confirmed, the patient will be withdrawn from study.&#xD;
&#xD;
          -  Time between initial surgery/biopsy and planned start of treatment (if allocated to&#xD;
             the experimental arm) ≤ 15 days (ideally in the first 7 days)&#xD;
&#xD;
          -  Karnofsky performance status (KPS) ≥ 60%, or KPS &lt;60% only related to glioma-related&#xD;
             motor paresis.&#xD;
&#xD;
          -  Adequate biological functions&#xD;
&#xD;
          -  Common toxicity criteria (CTC) non hematological adverse events ≤ Grade 1 (except for&#xD;
             alopecia, nausea, vomiting and neurological symptoms)&#xD;
&#xD;
          -  Females of child bearing potential must have a negative serum or urine pregnancy test&#xD;
             within 7 days prior to initiation of treatment. Sexually active patients must agree to&#xD;
             use adequate and appropriate contraception while on study drug and for 6 months after&#xD;
             stopping the study drug.&#xD;
&#xD;
          -  Standard radiation therapy deemed feasible (60 Gy, 30 fractions)&#xD;
&#xD;
          -  Time interval of less than 43 days between initial surgery/biopsy and planned start of&#xD;
             radiation therapy&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary or recurrent glioblastoma (GBM)&#xD;
&#xD;
          -  Planned use of tumor-treating electric fields&#xD;
&#xD;
          -  Planned use of Carmustine implants&#xD;
&#xD;
          -  Prior malignancy in the last 5 years before inclusion or concomitant&#xD;
&#xD;
          -  Severe myelosuppression&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs, study drug classes, excipients in&#xD;
             the formulation or to dacarbazine (DTIC)&#xD;
&#xD;
          -  Current or recent treatment with another experimental drug or patients included in a&#xD;
             clinical therapeutic trial (in the 30 days prior to inclusion).&#xD;
&#xD;
          -  Known current viral hepatitis, HIV infection or current active infectious disease&#xD;
&#xD;
          -  Inability to swallow oral medications or any mal-absorption condition&#xD;
&#xD;
          -  Pregnant or breastfeeding patients.&#xD;
&#xD;
          -  Inability to comply with medical follow-up of the trial (geographical, social or&#xD;
             psychic reasons)&#xD;
&#xD;
          -  Person under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence LEFRANC, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ERASME</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno CHAUFFERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie VANSEYMORTIER</last_name>
    <phone>33320295918</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHAUFFERT Bruno, MD, PhD</last_name>
      <email>Chauffert.Bruno@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno CHAUFFERT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre COUTTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne FESSART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine DESENCLOS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu BOONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soraya RAMDANE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farid BELKHIR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iona HRAB, MD</last_name>
      <email>i.hrab@baclesse-unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Iona HRAB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lien BEKAERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien GEFFRELOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dinu STEFAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyne EMERY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Hassanein BERRO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier DURANDO, MD</last_name>
      <email>Xavier.Durando@clermont.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier DURANDO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maureen BERNADACH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume DUPIC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toufic KHALIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido AHLE, MD</last_name>
      <email>guido.ahle@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>Guido AHLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claude GAULTIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David ATLANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jimmy VOIRIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GHIRINGELLI, MD, PhD</last_name>
      <email>fghiringhelli@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>François GHIRINGELLI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie VINCENT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François GUION, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles TRUC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walid FARAH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien PAVILLET, MD</last_name>
      <email>jpavillet@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Julien PAVILLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coralie FRENOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel DE SCHLICHTING, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François CAIRE, MD</last_name>
      <email>françois.caire@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>François CAIRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre CLAVERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elise DELUCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine LAVAU-DENES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69673</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice BONNEVILLE-LEVARD, MD</last_name>
      <email>Alice.BONNEVILLE-LEVARD@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Alice BONNEVILLE-LEVARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier FRAPPAZ, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Pierre SUNYACH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coralie MONCHARMONT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronan TANGUY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne DURAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CHINOT, MD</last_name>
      <email>olivier.chinot@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Maryline BARRIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal CAMPELLO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregorio PETRIRENA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emeline TABOURET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier MURACCIOLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henry DUFOUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas GRAILLON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Hugues ROCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel FABBRO, MD, PhD</last_name>
      <email>michel.fabbro@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Michel FABBRO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie CHASSIROUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine KERR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amélie DARLIX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc BAUCHET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc TAILLANDIER, MD</last_name>
      <email>l.taillandier@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Luc TAILLANDIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick BEAUCHESNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabien RECH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume VOGIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital de Cimiez</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique BOURG, MD</last_name>
      <email>bourg.v@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Véronique BOURG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine LEBRUN-FRENAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabien ALMAIRAC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khe HOANG XUAN, MD</last_name>
      <email>khe.hoang-xuan@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Khe HOANG XUAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed IDBAIH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence LAIGLE-DONADEY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agusti ALENTORN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline DEHAIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline HOUILLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dimitri PSIMARAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loïc FEUVRET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre CARPENTIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH René Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia RIZZO, MD</last_name>
      <email>claudia.rizzo@ght-novo.fr</email>
    </contact>
    <investigator>
      <last_name>Claudia RIZZO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis NGUYEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel MANDONNET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Cancérologie Loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole RAMIREZ, MD</last_name>
      <email>carole.ramirez@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Carole RAMIREZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain RIVOIRARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane Chloé TRONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MAGNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François VASSAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Jeannette MOTUO-FOTSO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges NOEL, MD, PhD</last_name>
      <email>gnoel@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Georges NOEL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland SCHOTT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène CEBULA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilyess ZEMMOURA, MD</last_name>
      <email>Ilyess.zemmoura@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Ilyess ZEMMOURA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe DESTRIEUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bérengère NARCISO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie CHAPET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>temozolomide</keyword>
  <keyword>Stupp protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

